The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

Twelve-Month Outcomes of the TaurusOne® Valve For Transcatheter Aortic Valve Implantation in Patients with Severe Aortic Stenosis

DOI: 10.4244/EIJ-D-21-00040

1. National Centre for Cardiovascular Disease, Fuwai Hospital, Beijing, China, China
2. West China Hospital, Sichuan University, Chengdu, China
3. The 2nd Affiliated Hospital ZheJiang University School of Medicine, Hangzhou,China
4. The 2nd XiangYa Hospital of Central South University,Changsha,China
5. General Hospital of Northern Theater Command,Shenyang,China
6. The 2nd Affiliated Hospital of Harbin Medical University, Harbin, China
7. McGill University Health Center, Montreal, Canada
Disclaimer:

As a public service to our readership, this article - peer reviewed by the Editors of EuroIntervention and external reviewers - has been published immediately upon acceptance as it was received in the last round of revision. The content of this article is the responsibility of the authors.

Please note that supplementary movies are not available online at this stage. Once a paper is published in its edited and formatted form, it will be accompanied online by any supplementary movies.

To read the full content of this article, please log in to download the PDF.

Background: In the last decade, Transcatheter Aortic Valve Implantation (TAVI) has rapidly developed in China. As TAVI progresses towards low surgical risk patients, the total number of TAVI procedures will grow exponentially. There is a need to develop a domestic TAVI device designed for Chinese patients.

Aims: To evaluate the safety and efficacy of a self-expanding valve (TaurusOne® transcatheter aortic valve system) in the treatment of patients with symptomatic severe aortic stenosis in China.

Methods: A prospective, multi-center, single arm study was designed to enroll 120 patients with symptomatic severe aortic stenosis receive TAVI using TaurusOne® valve. The primary endpoint was all-cause mortality at 1 year.  

Results: From September 2017 to April 2019, 120 patients were enrolled (35% bicuspid aortic valve, mean Society of Thoracic Surgeon (STS) score 9.95%). 1-year mortality in 120 patients (follow-up rate, 100%), was 6.7% (upper 95% confidence interval: 12.9%) which was significantly lower than the performance goal of 30% (P<0.0001). All stroke, myocardial infarction, paravavular leak ≥ moderate, new pacemaker implantation occurred in 4.4%, 1.8%, 0.8%, and 22.1% at 1-year. The hemodynamic results and quality of life scores also improved significantly. Patients with bicuspid valve had similar outcomes as those with tricuspid aortic valve.

Conclusions: The 1-year clinical results confirm the safety and efficacy of the TaurusOne® transcatheter aortic valve system in the treatment of patients with symptomatic severe tricuspid and bicuspid aortic stenosis.

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article
Brachial Arterial Access for PCI: an Analysis of the British Cardiovascular Intervention Society Database